Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

In <i>BRAF<sup>V600mut</sup></i> metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical...

Full description

Bibliographic Details
Main Authors: Baptiste Louveau, Fanelie Jouenne, Coralie Reger de Moura, Aurelie Sadoux, Barouyr Baroudjian, Julie Delyon, Florian Herms, Adele De Masson, Laetitia Da Meda, Maxime Battistella, Nicolas Dumaz, Celeste Lebbe, Samia Mourah
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
metastatic melanoma
BRAF inhibitor
MEK inhibitor
baseline genomic alterations
Online Access:https://www.mdpi.com/2072-6694/11/8/1203

Internet

https://www.mdpi.com/2072-6694/11/8/1203

Similar Items